Science & Programs
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
The world leader in a new class of drugs designed to regulate disease-associated epigenetics.
BETonMACE – a global Phase 3 clinical trial with the most advanced epigenetic drug outside of oncology.
Providing novel science, clinical and value-based health solutions to key stakeholders, including payer groups.
Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with high unmet medical need.
- : Resverlogix Publishes on Apabetalone’s Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
- : Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
- : Resverlogix Announces Warrant Repricing and One-Year Extension